LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Erlotinib | 10 | uM | LJP5 | 2 | M19 | 72 | hr | 1334 | 2814 | 4051 | 0.6946 | 0.5931 |
BT-20 | Erlotinib | 10 | uM | LJP5 | 3 | M19 | 72 | hr | 1334 | 2165 | 4117 | 0.5258 | 0.3467 |
BT-20 | Gefitinib | 0.04 | uM | LJP6 | 1 | N12 | 72 | hr | 1334 | 4119 | 3955 | 1.0413 | 1.0523 |
BT-20 | Gefitinib | 0.04 | uM | LJP6 | 2 | N12 | 72 | hr | 1334 | 4089 | 3899 | 1.0487 | 1.0624 |
BT-20 | Gefitinib | 0.04 | uM | LJP6 | 3 | N12 | 72 | hr | 1334 | 4355 | 3921 | 1.1106 | 1.1396 |
BT-20 | Gefitinib | 0.12 | uM | LJP6 | 1 | N11 | 72 | hr | 1334 | 4465 | 3955 | 1.1287 | 1.1606 |
BT-20 | Gefitinib | 0.12 | uM | LJP6 | 2 | N11 | 72 | hr | 1334 | 3960 | 3899 | 1.0156 | 1.0201 |
BT-20 | Gefitinib | 0.12 | uM | LJP6 | 3 | N11 | 72 | hr | 1334 | 3874 | 3921 | 0.9879 | 0.9844 |
BT-20 | Gefitinib | 0.37 | uM | LJP6 | 1 | N10 | 72 | hr | 1334 | 4050 | 3955 | 1.0238 | 1.0303 |
BT-20 | Gefitinib | 0.37 | uM | LJP6 | 2 | N10 | 72 | hr | 1334 | 3746 | 3899 | 0.9607 | 0.9489 |
BT-20 | Gefitinib | 0.37 | uM | LJP6 | 3 | N10 | 72 | hr | 1334 | 3699 | 3921 | 0.9433 | 0.9263 |
BT-20 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 1334 | 4074 | 3955 | 1.0299 | 1.0379 |
BT-20 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 1334 | 3737 | 3899 | 0.9584 | 0.9458 |
BT-20 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 1334 | 3734 | 3921 | 0.9522 | 0.9380 |
BT-20 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 1334 | 4008 | 3955 | 1.0132 | 1.0168 |
BT-20 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 1334 | 3685 | 3899 | 0.9451 | 0.9283 |
BT-20 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 1334 | 3413 | 3921 | 0.8704 | 0.8292 |
BT-20 | Gefitinib | 10 | uM | LJP6 | 1 | N07 | 72 | hr | 1334 | 3801 | 3955 | 0.9609 | 0.9497 |
BT-20 | Gefitinib | 10 | uM | LJP6 | 2 | N07 | 72 | hr | 1334 | 3469 | 3899 | 0.8897 | 0.8544 |
BT-20 | Gefitinib | 10 | uM | LJP6 | 3 | N07 | 72 | hr | 1334 | 3452 | 3921 | 0.8803 | 0.8426 |
BT-20 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 1334 | 4066 | 3930 | 1.0344 | 1.0439 |
BT-20 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 1334 | 4536 | 4051 | 1.1197 | 1.1463 |
BT-20 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 1334 | 3703 | 4117 | 0.8993 | 0.8736 |
BT-20 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 1334 | 4177 | 3930 | 1.0626 | 1.0795 |
BT-20 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 1334 | 4290 | 4051 | 1.0590 | 1.0728 |